Intermittent Fasting and Mediterranean Diet in Patient With Multiple Sclerosis

NCT ID: NCT06546033

Last Updated: 2024-08-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-02

Study Completion Date

2026-12-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

When the literature was reviewed, there is no study in which the effects of intermittent fasting and Mediterranean diet on quality of life, sleep, circadian rhythm and appetite hormones leptin and ghrelin levels in MS patients were evaluated and the two diet types were comparatively examined in terms of all these parameters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multiple Sclerosis (MS) is the most common chronic inflammatory disease affecting young adults between the ages of 20-40 years, which causes irreversible neurological damage and symptoms and is influenced by genetic and environmental factors on the Central Nervous System. Depression that may occur in MS patients leads to decreased motivation and negatively affects the quality of life. At the same time, depression may be accompanied by sleep disorders, anxiety, fatigue and eating disorders. Nutrition is recognised as one of the possible risk factors for the development of MS and has potential applications in the management and treatment of the disease. When the literature was reviewed, there is no study evaluating the effect of intermittent fasting and Mediterranean diet on quality of life, sleep, circadian rhythm and appetite hormones leptin and ghrelin levels in MS patients and comparing the two diet types in terms of all these parameters.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis Intermittent Fasting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The first group will be fed with Mediterranean diet The second group will be fed with intermittent diet
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1. Group (intermittent fasting)

Time Restricted Diet (10.00-18.00)

Group Type EXPERIMENTAL

application of different types of diet

Intervention Type OTHER

application of different types of diet

2. Group (mediterranean diet)

Diet based on the consumption of plant foods, cereals, oilseeds, etc.

Group Type EXPERIMENTAL

application of different types of diet

Intervention Type OTHER

application of different types of diet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

application of different types of diet

application of different types of diet

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To apply to the neurology outpatient clinic, to be a female between the ages of 18-65 who has been diagnosed with MS by a physician
* Not being in the attack period
* Not being in menopause Not being diagnosed with any autoimmune system disease other than -MS that may adversely affect the study,
* Not following the Mediterranean diet and intermittent fasting programmes in the last three months,
* Not being diagnosed with an eating behaviour disorder,
* Not having any communication problems,
* Signing the informed consent form,
* Brain MRI within the last three months,
* Not to be pregnant and lactating
* No physical disability No history of cancer
* Body Mass Index between 18,5 kg/m2- 29,9 kg/m2,
* Not losing 5% and/or more body weight in the last month

Exclusion Criteria

* Having a diagnosis of autoimmune system disease that may adversely affect working outside of -MS,
* To be in the attack period-Being under 18 years of age and over 65 years of age
* Being in menopause-Mediterranean diet and intermittent fasting feeding programmes within the last three months,
* Diet therapy that has an effect on the autoimmune system within the last three months,
* Being diagnosed with eating behaviour disorder,
* Having any communication problems,- Not signing the informed consent form,
* Failure to adapt to the work during the working period, to be in a situation/behaviour that may adversely affect the work,
* To have applied any nutritional intervention during the last three months prior to the study,
* Taking supplements such as selenium, zinc, iron, vitamin D and/or B12, which may affect the course of the study,
* To have received cancer treatment and / or to be receiving cancer treatment,
* Other neurological diseases (e.g. Parkinson's, epilepsy, Alzheimer's),
* Diagnosed with a disease lasting more than 4 months in the last 12 months and other specialised dietary / compositionally different dietary patterns (e.g. high protein, ketogenic, low energy content \< 1000 kcal/day),
* Body Mass Index \<18.5 kg/m2 or \>30 kg/m2
* Losing 5% and/or more body weight in the last month,
* Having a physical disability
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acibadem University

OTHER

Sponsor Role collaborator

Nigde Omer Halisdemir University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Elif Gökçe İNBAŞI

Lecturer, MSc.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nihan Çakır Biçer, PhD.

Role: STUDY_DIRECTOR

Acıbadem Mehmet Ali Aydınlar University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nigde Omer Halisdemir University

Niğde, Bor, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elif Gökçe İnbaşı, MSc.

Role: CONTACT

0388 311 86 00 ext. 2098

Nihan Çakır Biçer, PhD.

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Elif Gökçe İnbaşı, MSc.

Role: primary

0388 311 86 00 ext. 2098

Nihan Çakır Biçer, PhD.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-7/286

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.